PCSK9 and cardiovascular disorder: Recent trials using cholesterol absorption blocker ezetimibe in combination with statins [48] and proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors [49] clearly show that greater LDL-C reduction on top of statin therapy provides added benefits, without attenuation in cardiovascular disease benefit in patients starting treatment with lower LDL-C.